Contraindications to receiving the PNEUMOVAX23 (PPSV23) vaccine documented in Merck’s product insert include persons who have experienced a severe allergic reaction or anaphylaxis to any component of PNEUMOVAX23 (PPSV23).
PNEUMOVAX23 (PPSV23) should not be administered to children under the age of two and Merck warns that vaccination with PNEUMOVAX23 (PPSV23) should be deferred in individuals who are moderately or severely ill.
Caution is advised when vaccinating any person with a severely compromised pulmonary and/or cardiovascular function where a reaction may cause a significant health risk.
PNEUMOVAX23 (PPSV23) may not be effective for the prevention of pneumococcal meningitis persons who have cerebrospinal fluid leaks and persons with altered immune status may not respond effectively to vaccination.
Data on the administration of PNEUMOVAX23 to women who are pregnant is insufficient for Merck to provide any information on the risks of vaccination during pregnancy. It is also unknown whether PNEUMOVAX23 is found in human milk and as a result, Merck cautions the use of PNEUMOVAX23 in both pregnant and breastfeeding women.
